Federal Official Gazette
PUBLIC HEARING NOTICE ANS No. 68, OF AUGUST 11, 2026
THE NATIONAL SUPPLEMENTARY HEALTH AGENCY – ANS, in the exercise of its powers under Article 4 of Law No. 9,961 of January 28, 2000, Articles 32, 33 and 35 of Decree No. 3,327 of January 5, 2000, and in view of the decision rendered at the 641st Ordinary Meeting of the Board of Directors held on August 7, 2026, pursuant to Article 26 of Normative Resolution No. 548 of October 10, 2022, resolves to hold a PUBLIC HEARING on the following terms: Art. 1 The public hearing will address the preliminary recommendation not to incorporate the technologies covered by UAT No. 199 – Cholangioscopy, UAT No. 200 – Next-generation sequencing (NGS) panel and UAT No. 206 – Tepotinib hydrochloride. Art. 2 The public hearing will be held on August 20, 2026, from 9 a.m. to 1 p.m., virtually, via the Microsoft Teams platform.
OPERATING AUTHORIZATION
The National Supplementary Health Agency – ANS, in the exercise of the power conferred on it by Article 1 of Law No. 9,961 of January 28, 2000, as the body that oversees the activities that ensure supplementary health care, hereby announces the following. As of this date, Operating Authorization is granted to the Health Care Plan Operators listed below, after the Directorate of Standards and Qualification of Operators – DIOPE and the Directorate of Standards and Qualification of Products – DIPRO completed their analysis of the Operating Authorization proceedings, pursuant to Normative Resolution – RN No. 543 of September 2, 2022, and its subsequent amendments.
HEALTH POINT ADMINISTRADORA DE BENEFÍCIOS LTDA
42504-4
33910.019951/2026-96
ANS news
ANS debates prevention of El Niño risks in hospitals
For health plan operators, measures highlighted included strengthening coordination by Primary Health Care (APS), the use of telemedicine when necessary and the maintenance of communication channels with beneficiaries. “We want to act with rigor and discipline. We are opening this debate so that we can get organized right away,” stressed the Director-President.
Open public consultations
- CP 175. Subject: comments and suggestions on the preliminary recommendations not to incorporate the technologies covered by UAT No. 199 – Cholangioscopy, UAT No. 200 – Next-generation sequencing (NGS) panel and UAT No. 206 – Tepotinib hydrochloride. Deadline: Aug 12, 2026 to Aug 31, 2026
Scheduled public hearings
- AP 68. Subject: preliminary recommendation not to incorporate the technologies covered by UAT No. 199 – Cholangioscopy, UAT No. 200 – Next-generation sequencing (NGS) panel and UAT No. 206 – Tepotinib hydrochloride. Date: August 20, 2026, from 9 a.m. to 1 p.m., virtually, via the Microsoft Teams platform.
Open public calls for input
There are no open public calls for input.
Open public calls
Discount cards, prepaid cards, or related services. Deadline: From Jun 2, 2026 to Aug 18, 2026.
Other news
Health plans: profit of R$ 8.5 billion in the first half
Source: extra.globo.com · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.